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Increased adipose tissue lipogenesis is associated
with enhanced insulin sensitivity. Mice overexpress-
ing the Glut4 glucose transporter in adipocytes have
elevated lipogenesis and increased glucose toler-
ance despite being obese with elevated circulating
fatty acids. Lipidomic analysis of adipose tissue
revealed the existence of branched fatty acid esters
of hydroxy fatty acids (FAHFAs) that were elevated
16- to 18-fold in these mice. FAHFA isomers differ
by the branched ester position on the hydroxy
fatty acid (e.g., palmitic-acid-9-hydroxy-stearic-
acid, 9-PAHSA). PAHSAs are synthesized in vivo
and regulated by fasting and high-fat feeding.
PAHSA levels correlate highly with insulin sensitivity
and are reduced in adipose tissue and serum
of insulin-resistant humans. PAHSA administration
in mice lowers ambient glycemia and improves
glucose tolerance while stimulating GLP-1 and insu-
lin secretion. PAHSAs also reduce adipose tissue
inflammation. In adipocytes, PAHSAs signal through
GPR120 to enhance insulin-stimulated glucose up-
take. Thus, FAHFAs are endogenous lipids with the
potential to treat type 2 diabetes.INTRODUCTION
Obesity and type 2 diabetes (T2D) are at epidemic proportions
worldwide (Hu, 2011). The major pathogenic factors underlying
T2D are resistance to insulin action in peripheral tissues and
dysregulated insulin secretion. The Glut4 glucose transporter is318 Cell 159, 318–332, October 9, 2014 ª2014 Elsevier Inc.the major insulin-regulated glucose transporter and mediates
glucose uptake into skeletal muscle, heart, and adipocytes in
response to rising insulin after a meal (Shepherd and Kahn,
1999). In humans and rodents with obesity or T2D, Glut4 is
downregulated selectively in adipose tissue (AT) and not in mus-
cle (Shepherd and Kahn, 1999). This alters AT biology leading to
systemic insulin resistance (Abel et al., 2001). Glut4 knockdown
selectively in adipocytes in mice results in insulin resistance and
increased T2D risk (Abel et al., 2001), whereas adipose-selective
overexpression of Glut4 (AG4OX) lowers fasting glycemia and
enhances glucose tolerance (Carvalho et al., 2005; Shepherd
et al., 1993). These effects in AG4OX mice are mediated by
glucose-dependent induction of lipogenesis in AT driven by
ChREBP (Herman et al., 2012), a transcription factor that
regulates both glycolysis and lipogenesis (Iizuka et al., 2004;
Ma et al., 2005). ChREBP knockout in AG4OX mice completely
reverses the enhanced glucose tolerance (Herman et al.,
2012). Expression of ChREBP and lipogenic genes in AT is highly
associated with insulin sensitivity in humans and rodents (Her-
man et al., 2012; Roberts et al., 2009) and increased de novo
lipogenesis in AT has favorable metabolic effects including
potentially increasing longevity (Bruss et al., 2010).
Elevated circulating fatty acids are generally associated with
insulin resistance and glucose intolerance (Boden and Shulman,
2002). However, certain fatty acids such as dietary omega-3 fatty
acids (Oh et al., 2010; Virtanen et al., 2014) and the endoge-
nously produced palmitoleate (Cao et al., 2008) have favorable
metabolic effects. Furthermore, large epidemiological studies
show that an increased ratio of unsaturated to saturated fatty
acids in serum triacylglycerols is associated with a reduced
risk of T2D (Rhee et al., 2011; Rise´rus et al., 2009). Similarly,
an increased ratio of monounsaturated to saturated fatty acids
in the liver is associated with insulin sensitivity even with exten-
sive hepatic steatosis (Benhamed et al., 2012). AG4OX mice
have elevated circulating fatty acids and increased adiposity,
yet have lower fasting glycemia and profoundly enhanced
glucose tolerance compared to controls (Carvalho et al., 2005;
Herman et al., 2012; Shepherd et al., 1993). This raised the
possibility that enhanced AT lipogenesis in response to Glut4
overexpression might drive the production of lipids which have
favorable metabolic effects. Since Glut4 (Carvalho et al., 2005;
Shepherd and Kahn, 1999) and ChREBP (Herman et al., 2012)
expression are downregulated in AT in insulin-resistant humans
and rodents, the production of these metabolically favorable
lipids may be low in these states. To test these hypotheses, we
performed lipidomic analysis of AT from wild-type (WT) and
AG4OX mice.
RESULTS
Identification of a Class of Glut4-Regulated Lipids
Using a quantitative mass spectrometry (MS) lipidomics plat-
form (Saghatelian et al., 2004), we detected more than 1,400
ions in AT, 6% of which had a 2- to 4-fold difference between
AG4OX and WT mice. A cluster of ions in AG4OX AT was
elevated R16-fold (Figure 1A). The measured accurate mass
of these ions enabled us to calculate their molecular formulas
as C32H61O4 (509.4575), C34H63O4 (535.4732), C34H65O4
(537.4888), and C36H67O4 (563.5045). These formulas all contain
a unique signature of four oxygen atoms indicating that these
ions are members of a single lipid class. These formulas do
not correspond to any known metabolite in the Metlin (Smith
et al., 2005) and Lipid Maps (Sud et al., 2007) metabolite data-
bases. We hypothesized these lipids might contribute to
glucose-insulin homeostasis because of their abundance in
AG4OX mice, in which improved glucose tolerance depends
on enhanced AT lipogenesis (Herman et al., 2012). Therefore,
we proceeded to determine the molecular structures and bio-
logic effects of these lipids.
The mass differences among these ions suggested they
contain fatty acids. Fragmentation of the 537 ion generated
several product ions with masses of 255, 281, and 299 (Fig-
ure 1B), which correspond to palmitic acid (PA), octadecenoic
acid, and hydroxy-stearic acid (HSA), respectively. The molecu-
lar formula of the 537 ion (C34H65O4) does not contain any double
bonds. This indicates that octadecenoic acid, which contains a
double bond, results from fragmentation in the MS and is not
part of the natural metabolite. Based on the chemical formula
and the fact that this metabolite ionized only in the negative
mode, the most reasonable structure for the 537 ion is an ester
that combines PA and HSA to yield palmitic acid-hydroxy stearic
acid (PAHSA) (Figures 1B and 1C). Based on this structural
model and the masses detected for the other elevated ions, their
structures are: palmitic acid-hydroxy palmitic acid (PAHPA, m/z
509), oleic acid-hydroxy stearic acid (OAHSA, m/z 563), and the
535 ion is a mixture of palmitoleic acid-hydroxy stearic acid
(POHSA), and oleic acid-hydroxy palmitic acid (OAHPA) (Fig-
ure 1C). We refer to this class of natural-occurring lipids as fatty
acid-hydroxy fatty acids (Figures 1C and 1D), abbreviated as
FAHFAs. An additional ion, detected in positive ionization
mode, was also upregulated in AG4OX AT (Figure 1A) but the
molecular formula indicated it is not a FAHFA, and therefore
we did not characterize it further.Using a targeted MS approach, we identified 16 FAHFA family
members in mouse serum that consisted of four fatty acids and
four hydroxy-fatty acids in different combinations (Figure 1D).
FAHFAs with PO, PA, or OA as the fatty acid moiety and HPA
or HSA as the hydroxy-fatty acid moiety were most highly
increased in AG4OX compared toWTmice (Figure 1D). Because
PAHSAs were the most highly upregulated family member in AT
of AG4OX (Figure 1A), we investigated their biologic effects.
Tissue Distribution of Total PAHSAs in WT and AG4OX
Mice and Regulation by ChREBP
Targeted MS revealed PAHSAs in all tissues analyzed. In WT
mice, total PAHSA levels are highest in brown adipose tissue
(BAT) followed by subcutaneous (SQ) white adipose tissue
(WAT), perigonadal (PG) WAT, and liver (Figure 1E). Total PAHSA
levels are very low in heart and gastrocnemius muscle (data not
shown). PAHSA levels vary >7-fold among tissues in WT mice
(Figure 1E). In WT serum, total PAHSA levels are 7 nM (Fig-
ure 1E). In AG4OX mice, total PAHSA levels are 16- to 18-fold
elevated in SQ and PGWAT, 3-fold in BAT and 2-fold in serum
compared to WT mice (Figure 1E). In contrast, PAHSA levels in
liver of AG4OXmice are30% lower than WT. Thus, Glut4 over-
expression in AT results in broad systemic regulation of PAHSAs
with tissue-specific alterations.
Because ChREBP regulates AT lipogenesis in AG4OX, we
testedwhetherChREBP regulatesPAHSA levels in vivo.ChREBP
knockout in normal mice reduces total PAHSA levels 75% in
PG- and SQ-WAT with no change in serum (Figure 1F). Knocking
outChREBP inAG4OXcompletely reverses themarked elevation
in PAHSA levels in PG- and SQ-WAT and serum.
Tissue Distribution of Specific PAHSA Isomers
and Regulation in WT and AG4OX Mice
We observed multiple peaks in the chromatograms that corre-
spond to different PAHSA isomers with the ester connected
to a different carbon of the hydroxy-fatty acid resulting in a
branched lipid. Fragmentation of PAHSAs from AT using high
collisional energy tandem MS (Moe et al., 2004) produced two
ions at 127 and 155 (Figure 1B) indicating that the ester is at
the 9th carbon of the HSA (Figure 1C). We refer to this isomer
as 9-PAHSA, which was confirmed by chemical synthesis and
coelution with 13C-9-PAHSA (Figure 2A). We also discovered
PAHSAs with branched esters at carbons 5, 7, 8, 10, 11, 12,
and 13 verified by comparison to synthetic standards (Figure 2A).
Thus, there are at least eight PAHSA isomers. We achieved
complete separation of all isomers except 13- and 12-PAHSA
(Figure 2A), which we quantify together in all data sets.
We sought to determine which PAHSA isomers are upregu-
lated inWAT and serum of AG4OXmice as an initial clue to which
ones may have biologic activities that could affect glucose ho-
meostasis. In WT serum, 13/12-, 11-, 10-, 9-, and 5-PAHSA
are present at 0.4–2.5 nM, which is the range for signaling lipids
such as prostacyclins, prostaglandins, steroids, and endocan-
nabinoids. In WT WAT and BAT, 9-PAHSA is the most abundant
isomer (Figure 2B). 13/12-, 11-, and 10-PAHSA are present
at 20%–30% of 9-PAHSA levels and 8-, 7-, and 5-PAHSA are
present at substantially lower concentrations (Figure 2B).
Surprisingly, liver which is also a lipogenic tissue, has onlyCell 159, 318–332, October 9, 2014 ª2014 Elsevier Inc. 319
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Figure 1. Discovery and Characterization of a Class of Lipids (FAHFAs)
(A) Comparative lipidomics of SQwhite adipose tissue (WAT) fromAG4OX andWTmice reveals the presence of a group of ions atm/z 509 (PAHPA), 535 (POHSA/
OAHPA), 563 (OAHSA), and 537 (PAHSA) that are elevated 16- to 18-fold in AG4OX mice.
(legend continued on next page)
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13/12- and 9-PAHSAs (Figure 2B). In AG4OX mice, all PAHSA
isomers are elevated in serum, SQ and PG WAT and BAT with
9-PAHSA being the most highly upregulated. In contrast, in
AG4OX liver, PAHSA isomers are reduced compared to WT.
These data reveal that individual PAHSA isomers are coordi-
nately upregulated in AG4OX WAT and BAT which may result
from the effect of increased Glut4 to induce ChREBP and
lipogenesis in these tissues (Herman et al., 2012; Tozzo et al.,
1995). However, PAHSAs are reduced in AG4OX liver indicating
tissue-specific mechanisms for regulating uptake, synthesis,
degradation or release.
This is further indicated by the tissue distribution of specific
PAHSA isomers in WT mice. 13/12- and 9-PAHSAs are present
in all WT tissues examined (Figure 2C). 9-PAHSA is more abun-
dant in AT than liver while 13/12-PAHSA is not. In contrast to
13/12- and 9-PAHSA, 5-PAHSA is restricted to AT, kidney, and
serum (Figure 2C).
Physiologic Regulation of PAHSAs with Fasting
We examined PAHSA regulation with fasting (Figure 2D). In the
fed state, total PAHSA levels are highest in BAT; slightly lower
in SQ and PG WAT; and substantially lower in liver, pancreas,
and kidney (Figure 2D). Fasting increases PAHSAs 2- to 3-fold
in WAT and kidney and 65% in pancreas but does not alter
the levels in BAT, liver, or serum (Figure 2D). Hence, PAHSAs
undergo tissue-specific regulation with fasting (Figure 2D). The
fasting-induced increase in PAHSAs in WAT is surprising since
one would expect synthesis to be lower due to reduced lipogen-
esis andChREBPwith fasting. Indeed, in spite of elevatedPAHSA
levels, biosynthetic activity (described below) was not increased
in WAT from fasted mice (data not shown). This may reflect inhi-
bition of degradation or release. To better understand the mech-
anism, we determined fasting effects on PAHSA levels in AG4OX
mice. Fasting further elevated PAHSAs in WAT but not in BAT or
serum (Figure S1 available online). Since PAHSA levels in AG4OX
WAT are regulated by ChREBP-driven lipogenesis (Figure 1E)
and lipogenesis is not increased with fasting, these data demon-
strate an additional level of regulation and support the possibility
that fasting inhibits PAHSA degradation or release.
We also investigated regulation of individual PAHSA isomers
with fasting (Figure 2E). Although total PAHSA levels are un-
changed in serum of fasted mice (Figure 2D), specific isomers
(10-, 9- and 5-PAHSA) are modestly decreased (Figure 2E).
In SQ and PG WAT, most of the isomers (13/12-, 11-, 10-, 9-,
and 8-PAHSA) including the more abundant ones are increased
with fasting while 7- and 5-PAHSA are unchanged (Figure 2E).
Fasting had no effect on any PAHSA isomer in BAT or liver while(B) Structural analysis of the 537 ion from AG4OX WAT by tandem MS demons
(m/z 299). Octadecanoic acid (m/z 281) results from the dehydration of hydroxy s
127 and 155, identifying carbon 9 as the position of the hydroxyl group on hydro
(C) Acyl chain carbon numbering scheme, molecular formula, mass and names o
m/z 535 (POHSA or OAHPA) ions.
(D) Constituent fatty acid and hydroxy-fatty acid components of FAHFAs. Quantifi
(E) Total PAHSA levels in serum and tissues of WT and AG4OXmice. Inset, liver to
other tissues within the same genotype (ANOVA).
(F) Total PAHSA levels in SQ-WAT, PG-WAT, and serum of WT, AG4OX, ChREBP
genotypes within same tissue or serum (ANOVA), # p < 0.05 versus AG4OX and
Data are means ± SEM. MRM transitions for detection of different FAHFAs can ball isomers were upregulated in kidney. In pancreas, 11- and 9-
PAHSA are increased with fasting while 13/12- and 7-PAHSA
are unchanged. Thus, PAHSA isomer levels undergo tissue-
specific and isomer-specific regulation with fasting (Figure 2E).
The abundance of different PAHSA isomers in the fasted state
differs by 60-fold in a given tissue (compare 9- with 5-PAHSA
in SQ WAT) (Figure 2E). These results suggest that fasting
regulates pathways involved in synthesis, degradation, and/or
release of specific PAHSA isomers in a tissue- and isomer-
specific manner.
Regulation of PAHSAs in Obesity and Insulin Resistance
We investigated PAHSA levels in insulin-resistant mice with
high-fat-diet (HFD)-induced obesity (Figure 3A). After 9 weeks
of HFD, mice were obese and diabetic (determined by GTT)
(Figure S2A). HFD had differential effects on specific PAHSA
isomers. 5- and 13/12-PAHSAs were downregulated in HFD
mice in serum, PG and SQ WAT and BAT (Figure 3A) although
the difference did not reach significance for 13/12-PAHSA in
PG WAT. Strikingly, 10-, 9-, 8-, and 7-PAHSA were increased
in PG WAT of HFD-fed mice. Most of these isomers were
decreased in SQ WAT and BAT and unchanged in serum
(Figure 3A). Total lipid ion signal measured in SQ WAT was
unchanged between chow- and HFD-fed mice (Figure S2B).
13/12- and 9-PAHSA were also decreased in liver (Figure 3A).
These studies demonstrate: (1) 5-PAHSA and 13/12-PAHSA
are consistently reduced in AT depots with HFD while other
PAHSA isomers have opposite regulation among the depots
(PG WAT versus SQ WAT and BAT) (Figure 3A); and (2) Only
two of the five isomers in serum are reduced with HFD (Fig-
ure 3A). Thus, PAHSAs undergo isomer-specific and tissue-spe-
cific regulation under insulin-resistant conditions in WT mice.
PAHSAs Are Present in Food
To determine whether the changes in PAHSA levels in altered
metabolic states could result from differences in dietary intake,
we measured PAHSA levels in rodent and human foods. In
chow and HFD, we found five of the seven isomers that are pre-
sent in mouse AT, 13/12-, 11-, 10-, 9-, and 8-PAHSA, but not 7-
and 5-PAHSA. However, the relative abundance among isomers
was strikingly different from AT or serum with 10-PAHSA being
most abundant in both diets (Figure 3B). Levels of all these iso-
mersweresubstantially lower inHFD thanchow (Figure3B).Given
that PAHSAs increase in WAT during fasting (Figures 2D and 2E),
regulation of tissue PAHSA levels does not simply reflect dietary
intake. Similarly, the abundance of PAHSA isomers in serum and
tissues (Figure 2C) does not correlate with predominant isomerstrates that it is composed of palmitic acid (m/z 255) and hydroxy stearic acid
tearic acid. Fragmentation at high collision energies produces two ions at m/z
xy-stearic acid, confirming the structure to be 9-PAHSA.
f FAHFAs from the m/z 537 (PAHSA), m/z 509 (PAHPA), m/z 563 (OAHSA), and
cation of 16 FAHFA family members identified in serum ofWT and AG4OXmice.
tal PAHSA levels. n = 3–5/group, *p < 0.05 versusWT (t test), yp < 0.05 versus all
KO, and AG4OX/ChREBP KO mice. n = 3–5/group, *p < 0.05 versus all other
ChREBP-KO.
e found in Table S1.
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Figure 2. Identification and Quantification of PAHSA Isomers in Mouse Serum and Tissues
(A) Coelution of PAHSA isomers from serum and SQWAT of WT and AG4OXmice with synthetic standards for individual PAHSA isomers. The peak for 5-PAHSA
is shown in red in the inset. Note: different y axis scale for WT SQ WAT (Red numbers) versus AG4OX SQ WAT.
(B) Distribution and quantification of PAHSA isomers in serum and tissues of WT and AG4OX mice. ‘‘Ester position’’ refers to the location of the ester bond in
PAHSA isomers. n = 3–5/group, *p < 0.05 versus WT (t test).
(C) Distribution and quantification of 13/12-, 9-, and 5-PAHSA isomers in serum and tissues of WT female FVB mice. n = 3–5/group, a,b,c Tissues with different
letters are different from each other within the same isomer panel (p < 0.05, ANOVA).
(D and E) Total PAHSA levels (D) and PAHSA isomer levels (E) in serum and tissues of WTmice in fed or fasted (16 hr) states. ‘‘Ester position’’ refers to the location
of the ester bond in PAHSA isomers. n = 3–5/group, *p < 0.05, # < 0.07 versus fed (t test) a,b,c,dTissues with different letters are different from each other for the fed
state (p < 0.05, ANOVA).
Data are means ± SEM. See also Figure S1.in chow (Figure 3B), suggesting that PAHSAs present in tissues
are synthesized endogenously. The fact that 5-PAHSA is not pre-
sent inmousechoworHFD (Figure3B)but ispresent inWAT,BAT,
kidney, and serum (Figures 2A–2C, 2E and 3A) further supports
this notion. We also found PAHSAs in all human foods tested
with different isomer distributions and abundance (Figure S2C).
PAHSAs Are Synthesized in Mammalian Tissues
To determine whether PAHSAs are synthesized endogenously,
we investigated PAHSA biosynthesis in liver and WAT lysates of
normal mice. We detected PAHSA biosynthetic activity in both322 Cell 159, 318–332, October 9, 2014 ª2014 Elsevier Inc.tissues, and it was markedly reduced by heat denaturation (Fig-
ure 3C). We also detected PAHSA biosynthesis in vivo. Gavage
of mice with 9-hydroxy heptadecanoic acid (9-HHA), a hydroxy
fatty acid not normally found in mammalian tissues resulted in
synthesis of full-length FAHFAs containing a 9-HHA acyl chain
indicating that FAHFAs can be synthesized in vivo (Figure 3D).
PAHSAsAre Present in Humans and Levels Are Reduced
with Insulin Resistance
To determine if PAHSAs are present in humans and are regulated
in disease states, wemeasured PAHSA isomers in serumandSQ
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Figure 3. PAHSA Isomer Levels in Tissues of Mice on Chow or HFD, PAHSA Isomer Levels in Food, and PAHSA Biosynthesis In Vivo and in
Tissues In Vitro
(A) Quantification of PAHSA isomers in serum, SQWAT, PGWAT, BAT, and liver ofWT female FVBmice fed on chow or HFD for 9weeks. ‘‘Ester position’’ refers to
the location of the ester bond in PAHSA isomers. n = 3–6/group, *p < 0.05 versus chow (t test).
(B) Quantification of PAHSA isomers in mouse chow and HFD. n = 3/group.
(C) 9-PAHSA levels in liver and PG-WAT lysates incubated with palmitoyl-CoA and 9-hydroxy stearic acid and heat-denatured Controls. n = 3/group, *p < 0.05
versus heat-denatured Controls (t test).
(D) 9-palmitic-acid-hydroxy-heptadecanoic-acid (9-PAHHA) serum levels in mice 3 hr postgavage with 9-hydroxy-heptadecanoic-acid (9-HHA) or vehicle
control. n = 3/group, *p < 0.05 versus vehicle (t test).
Data are means ± SEM. See also Figure S2.WAT from insulin-sensitive and insulin-resistant nondiabetic
humans. Subjects were middle-aged. BMI was increased in
five out of six insulin-resistant participants (Table S2). Insulin
resistance was demonstrated by a 61% reduction in glucose
infusion rate during a euglycemic hyperinsulinemic clamp (Table
S2). Serum triglycerides and free fatty acids in the fasting state
were not different between groups (Table S2). Total PAHSA
levels are reduced 40% in serum of insulin-resistant humans
(Figure 4A). In serum of both insulin-sensitive and insulin-
resistant humans, 9- and 10-PAHSA are most abundant and
13/12- and 5-PAHSAs are present at 1/5 of these concentra-
tions (Figure 4A). In insulin-resistant people, serum levels of all
PAHSAs except 9-PAHSA are reduced by 40%–55% compared
to insulin-sensitive people (Figure 4A). Serum concentrations oftotal PAHSAs and all isomers correlated remarkably strongly
with insulin sensitivity measured by clamp (Figure 4B). Serum
PAHSA levels did not correlate with levels of nonesterified fatty
acids or triglycerides (data not shown) suggesting that PAHSA
levels are regulated by different mechanisms.
In human SQ WAT, total PAHSAs are reduced 70% (Fig-
ure 4C). We detected 13/12-, 11-, 10-, 9-, and 5-PAHSA isomers
in these biopsies (Figure 4C). However, for technical reasons we
were unable to quantify the levels of 11-PAHSA. 9-PAHSA levels
were higher than all other isomers (Figure 4C) similar to mouse
SQ WAT (Figures 2B, 2E and 3A). 13/12-, 10-, 9-, and 5-PAHSA
concentrations in SQ WAT of insulin-resistant people were
60%–73% lower than in insulin-sensitive people (Figure 4C).
Concentrations of total PAHSAs and of 9- and 5-PAHSA isomersCell 159, 318–332, October 9, 2014 ª2014 Elsevier Inc. 323
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in WAT correlate highly with insulin sensitivity (Figure 4D). Serum
PAHSA levels correlated with WAT PAHSA levels only for 5-
PAHSA (Figure 4E).
In summary, all PAHSA isomers detected are reduced in SQ
WAT in insulin-resistant subjects and all but one are reduced in
serum. Furthermore, PAHSA levels in serum and WAT correlate
highly with whole-body insulin sensitivity. These effects parallel
the effects in diet-induced obese mice in which all PAHSA iso-
mers are reduced in SQ WAT, and 13/12- and 5-PAHSA are
lower in serum compared to chow-fed mice (Figure 3A). Thus,
the regulation of PAHSAs and their inverse correlation with
insulin resistance is conserved between mice and humans.
PAHSAs Acutely Improve Glucose Tolerance
and Ambient Glycemia
Since levels of PAHSA isomers correlate with insulin sensitivity
(Figures 4B and 4D), we tested whether administration of
PAHSAs could improve glucose homeostasis in obese, diabetic
mice. We selected 9-PAHSA and 5-PAHSA because: (1)
9-PAHSA was the most abundant form in WAT and BAT in WT
mice (Figure 2B) and in SQ WAT of humans (Figure 4C). (2)
9-PAHSA is the most strongly upregulated in serum and WAT
of insulin-sensitive AG4OX mice (Figure 2B) and was downregu-
lated (with other isomers) in WAT of insulin-resistant humans
(Figure 4C). (3) 5-PAHSA was the most consistently downregu-
lated in all adipose depots and in serum of insulin-resistant
mice (Figure 3A) and in WAT and serum of insulin-resistant
humans. Oral gavage of 5-PAHSA increased serum levels 3- to
5-fold in mice on chow and HFD (Figure S3). As shown in Fig-
ure 3A, baseline 5-PAHSA levels were 50%–80% lower in
HFD-fed mice compared to chow-fed mice and 5-PAHSA
gavage more than restored the levels (Figure S3). The elevation
of serum 5-PAHSA levels after gavage in both chow and HFD-
fed mice was similar to the elevation in serum of AG4OX mice
(Figures 2B and S2). This indicated that PAHSAs are absorbed
orally and this route of administration can be used to increase
PAHSA concentrations for in vivo metabolic studies.
Acute oral administration of 5- or 9-PAHSA in insulin-resistant
HFD-fed mice lowered basal glycemia at 30 min after PAHSA
administration (Figure 5A, 30 to 0 min). Subsequently, glucose
was administered and we observed improved glucose tolerance
in PAHSA-treated mice with reduced area under the glucose
excursion curve (Figure 5A). Because of the significant effect of
PAHSAs on the baseline glucose levels in HFD-fed mice at
30 min after administration, we tested whether PAHSA action to
lower baseline glycemia was sustained. 5-PAHSA or 9-PAHSA
had a greater glucose-lowering effect than vehicle treatment in
HFD-fed mice also at 2.5–3 hr after administration (Figure 5B).Figure 4. PAHSA Levels Are Decreased in Insulin-Resistant Humans a
(A) Quantification of total PAHSAs and individual PAHSA isomers in serum of
metabolic characteristics). n = 6–7/group.
(B) Correlation between insulin-sensitivity (clamp glucose infusion rate) and seru
(C) Quantification of total PAHSA and individual PAHSA isomers in SQ WAT of in
(D) Correlation between insulin-sensitivity (clamp glucose infusion rate) and SQ W
(E) Correlation between SQWAT and serum 5-PAHSA levels. LBM: lean body mas
test, A and C).
Data are means ± SEM for (A and C). Correlations were determined by linear regThere was no difference in plasma insulin levels at this time in
PAHSA-treated compared to vehicle-treated mice (data not
shown). Since no food was available during this study, calorie
absorption was not a variable and the results suggest that oral
PAHSA administration enhances insulin sensitivity. An insulin
tolerance test showed lower glucose levels in PAHSA-treated
mice compared to vehicle-treated mice for the study duration
(120 min after insulin administration) which was largely because
of the PAHSA effect to lower baseline glycemia (data not shown).
PAHSAs Stimulate Insulin and GLP-1 Secretion
To determine whether enhanced insulin secretion might contri-
bute to the PAHSA-induced improvement in glucose tolerance
(Figure 5A), we tested PAHSA effects on glucose-stimulated in-
sulin secretion (GSIS) in vivo in aged chow-fed mice. 5-PAHSA
improved glucose tolerance (Figure 5C) concurrent with acute
enhancement of insulin secretion at 5 min after glucose adminis-
tration (Figure 5D). This may result from direct effects on insulin
secretion or from stimulation of incretin secretion since GLP-1
levels were also increased in PAHSA-treated mice at 5 min after
glucose administration (Figure 5E). Thus, PAHSAs augment the
acute stimulation of GLP-1 and insulin secretion in response to
glucose and these effects most likely have an important role in
the enhanced glucose tolerance following a single PAHSA dose.
To determine whether the stimulation of insulin secretion is a
direct effect of PAHSAs on pancreatic beta cells, we incubated
islets from human donors (Table S3, donors’ metabolic parame-
ters) with 5-PAHSA andmeasured GSIS. 5-PAHSA had no effect
on insulin secretion at 2.5 mMglucose but augmented the insulin
secretion response at 20 mM glucose (Figure 5F). These data
demonstrate that 5-PAHSA directly enhances GSIS in human
islets. To determine whether PAHSAs directly stimulate GLP-1
secretion, we used the enteroendocrine cell line STC-1. Both
5- and 9-PAHSA rapidly stimulated GLP-1 secretion from
STC-1 cells in a dose-dependentmanner (Figure 5G). The effects
are similar to those with the omega-3 fatty acid, a-linolenic acid,
and a synthetic GPR120 ligand (Figure 5G). Thus, the rapid
effects of PAHSAs to augment GSIS may be both direct effects
on pancreatic beta cells and indirect effects through stimulation
of GLP-1 secretion.
PAHSAs Enhance Insulin-Stimulated Glucose Transport
and Glut4 Translocation by Activating GPR120
To further understand the mechanism(s) by which PAHSAs
improve glucose homeostasis, we tested their effects on glucose
transport in adipocytes. PAHSAs increased glucose transport at
submaximal and maximal insulin concentrations (Figure 6A).
Neither of the fatty acids that form the parent PAHSA structure,nd Levels Correlate with Insulin Sensitivity
insulin-sensitive and insulin-resistant nondiabetic humans (see Table S2 for
m total PAHSA and individual PAHSA isomers. n = 13.
sulin-sensitive and insulin-resistant humans. n = 6–7/group.
AT total PAHSA and individual PAHSA isomers. n = 13.
s. Individual p values are shown on graphs, *p < 0.05 versus insulin-sensitive (t
ression analysis for (B, D, and E).
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Figure 5. PAHSAs Improve Glucose Tolerance and Ambient Glycemia In Vivo and Augment Insulin and GLP-1 Secretion
(A) 4.5 hr after food removal, HFD-fed mice were gavaged with 5-PAHSA (top), 9-PAHSA (bottom) or vehicle control. 30 min later an oral glucose tolerance test
(OGTT) was performed. n = 12–14/group, mice were on HFD for 42–52 weeks. *p < 0.05 versus vehicle at same time (t test). Area under the curve (AUC) was
calculated from 30 to 120 min. *p < 0.05 versus vehicle (t test).
(B) 2.5 hr after food removal, HFD-fedmice were gavaged with 5-PAHSA (top), 9-PAHSA (bottom) or vehicle control. Glycemia wasmeasured immediately before
(time 0) and at 2.5 hr (5-PAHSA) or 3 hr (9-PAHSA) after PAHSA gavage. n = 12–14/group. *p < 0.05 versus vehicle (t test).
(C) 4.5 hr after food removal, aged, chow-fedmice (45-week-old) were gavagedwith 5-PAHSA 30min prior to an OGTT. n = 12–14/group. *p < 0.05 versus vehicle
at same time (t test). Area under the curve (AUC) was calculated from 30 to 120 min. *p < 0.05 versus vehicle (t test).
(D and E) Serum insulin levels (D) and serum GLP-1 levels (E) 5 min postglucose challenge in chow-fed mice gavaged with 5-PAHSA or vehicle (glucose values
shown in C). n = 12–14/group, *p < 0.05 versus vehicle (t test).
(F) Insulin secretion from primary human islets from two independent donors. Islets were incubated with low (2.5 mM) or high (20 mM) glucose ex vivo in the
presence of 5-PAHSA (20 mM) or Control (KRB buffer). Diluent for 5-PAHSA was methanol (0.25%). n = 100 islets/condition, *p < 0.05 versus control 2.5 mM
glucose (t test), #p < 0.05 versus all treatments at 2.5 mM glucose (t test), $p < 0.05 versus control and diluent at 20 mM glucose (t test).
(G) Active GLP-1 secretion from STC-1 cells in response to 5-PAHSA (5P), 9-PAHSA (9P), a-Linolenic Acid (ALA), GW9508 (GW), or vehicle control (CTL, DMSO).
n = 4/group, *p < 0.05 versus vehicle (CTL) (t test).
Data are means ± SEM. See also Table S3 and Figure S3.
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Figure 6. PAHSAs Regulate Glucose Uptake and Glut4 Translocation via GPR120
(A) Insulin-stimulated glucose transport in 3T3-L1 adipocytes treated with 9-PAHSA (20 mM) or vehicle (DMSO) control for 6 days. n = 6/group, *p < 0.001 versus
vehicle (DMSO) at the same insulin concentration (ANOVA).
(B) Glucose transport in 3T3-L1 adipocytes treated for 48 hr with 9-PAHSA, 5-PAHSA, palmitic acid (PA), 9-hydroxy stearic acid (HSA) at 20 mMor their respective
vehicle controls (DMSO for 9- and 5-PAHSA. Ethanol for PA and HSA). n = 6/group. a,b,cgroups with different letters are different from each other p < 0.05
(ANOVA).
(C) Dose response of 9-PAHSA on GPR120 binding and receptor activation. n = 3 wells/condition.
(D) Insulin (10 nM)-stimulated glucose transport in 3T3-L1 adipocytes transfected with control siRNA (CTL) or GPR120 siRNA and treated with 5-PAHSA (10 mM),
9-PAHSA (10 mM) or vehicle (DMSO) control for 2 days. n = 3/group, *p < 0.05 versus control siRNA or GPR120 siRNA with DMSO without insulin (ANOVA),
$p < 0.05 versus all other conditions except each other (ANOVA).
(E) Glut4 plasma membrane translocation in 3T3-L1 adipocytes transfected with control siRNA or GPR120 siRNA and treated with 9-PAHSA in the presence or
absence of insulin. Scale bar = 50 mm.
(F) Quantification of Glut4 translocation in (E). Bars show means of six independent experiments without siRNA knockdown and three with siRNA knockdown.
Each experiment had an nR 50 cells/condition.*p < 0.05 versus everything else at same insulin concentration (ANOVA). All data are means ± SEM. See also
Figure S4.palmitic acid or hydroxystearic acid, alone improved insulin-
stimulated glucose transport (Figure 6B). The effects of PAHSAs
on insulin-stimulated glucose transport occurredwith both acute
(30 min) and chronic (2–6 day) treatment and at concentrations
as low as 500 nM (Figure S4A). PAHSAs did not alter total cellular
Glut1 or Glut4 protein levels in adipocytes even after 6 days of
incubation (data not shown).
Bioactive lipids can influence biology through binding to cell
surface receptors such as G protein-coupled receptors (GPCRs)
(Hara et al., 2013). The effects of PAHSAs on GLP-1 secretion
and glucose transport are consistent with possible activation
of GPCRs (Hirasawa et al., 2005). To determinewhether PAHSAs
activate GPCRs, we screened a panel of known lipid-activated
GPCRs. Both 9-PAHSA (Figure 6C) and 5-PAHSA (data not
shown) dose-dependently bind to and activate GPR120 whichis also activated by u-3 fatty acids and monounsaturated fatty
acids (Hirasawa et al., 2005; Oh et al., 2010). Activation of
GPR120 increases glucose transport and Glut4 translocation in
adipocytes (Oh et al., 2010). To test whether GPR120 mediates
the effects of PAHSAs, we knocked it down >95% in adipocytes
with siRNA (Figure S4B). This completely reversed the enhanced
effects of PAHSAs on insulin-stimulated glucose transport (Fig-
ure 6D). These data demonstrate that GPR120 mediates the
effects of PAHSAs on insulin-stimulated glucose transport.
To determine the mechanism for enhancement of glucose
transport with PAHSAs, we analyzed the effects on insulin-
induced Glut4 translocation to the plasma membrane in adipo-
cytes. In the absence of insulin, PAHSAs had no effect on
Glut4 translocation (Figure 6F). However, PAHSAs enhanced
Glut4 translocation at submaximal and maximal insulinCell 159, 318–332, October 9, 2014 ª2014 Elsevier Inc. 327
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concentrations (Figures 6E and 6F). These data indicate that
PAHSAs augment insulin-stimulated glucose transport by
enhancing Glut4 translocation. Knockdown of GPR120 in adipo-
cytes completely blocked the effect of PAHSAs to augment
insulin-stimulated Glut4 translocation (Figures 6E and 6F). We
obtained this effect with two different GPR120 siRNAs indicating
that it is a specific ‘‘on target’’ effect. These data together
demonstrate that PAHSAs bind to and activate GPR120 (Fig-
ure 6C), which mediates the effects of PAHSAs on insulin-stimu-
lated glucose transport and Glut4 translocation (Figures 6D–6F).
PAHSAs Exert Anti-Inflammatory Effects
Fatty acids, such as u-3 fatty acids, can elicit anti-inflammatory
effects through GPR120 (Oh et al., 2010). GPR120 is expressed
in bone-marrow-derived dendritic cells (BMDCs), which are
initial antigen-presenting cells in the innate immune response.
Innate immunity is activated in WAT in obesity and may
contribute to the insulin-resistant state (Lumeng and Saltiel,
2011). Saturated fatty acids such as palmitic acid and path-
ogen-derived molecules, such as lipopolysaccharide (LPS),
promote BMDC maturation by activating Toll-like receptors
(TLRs) (Lumeng and Saltiel, 2011). This induces expression of
proinflammatory cytokines, major histocompatibility complex II
(MHC II), and costimulatory molecules (CD40, CD80, and
CD86) required for antigen presentation and T cell activation.
LPS addition to BMDCs robustly increased CD80, CD86, CD40,
and MHC II expression, demonstrating the expected activation
of BMDCs (Figure 7A). 9-PAHSA blocked the LPS effect on
BMDC activation as evidenced by inhibition of LPS-induced
CD80, CD86, CD40, and MHC II expression (Figures 7A and
7B). Neither palmitic acid which is a component of the PAHSA
molecule, nor the mono-unsaturated fatty acid, oleic acid, ex-
erted these effects at a concentration (20 mM) (Figure S5) at
which 9-PAHSAhad strong anti-inflammatory effects (Figure 7B).
9-PAHSA completely blocked LPS-induced IL-12 secretion in a
dose-dependent manner (Figure 7C) and substantially reduced
IL-1b and TNFa at doses as low as 8 mM (Figure 7C). These
data indicate that 9-PAHSA has anti-inflammatory effects.
To test whether PAHSAs exert anti-inflammatory effects
in vivo, we measured TNFa and IL-1b in AT macrophages
(ATMs) from HFD-fed mice gavaged with 9-PAHSA or vehicle
for 3 days. The percentage of ATMs expressing TNFa, IL-1b,
or both was elevated in HFD-fed mice compared to chow.Figure 7. 9-PAHSA Inhibits LPS-Induced Dendritic Cell Maturation In V
Macrophages In Vivo
(A) LPS induces dendritic cell (DC) maturation (increased percentage of CD11c
This LPS effect is reduced in the presence of 9-PAHSA (40 mM) compared to v
costimulatory molecules from the panel above. n = 3 mice/group.
(B) LPS-induced DC maturation is inhibited by increasing concentrations of 9-PA
median fluorescence intensity. n = 3 mice/group.
(C) LPS–induced cytokine secretion from DC’s is inhibited by increasing concen
Red triangles represent vehicle for 9-PAHSA (DMSO, ‘‘-’’) without LPS. n = 3 mic
(D) Flow cytometry representation of AT macrophages expressing TNFa and IL
(30 mg/kg for chow mice and 45 mg/kg for HFD mice) or vehicle control. PG-WAT
with PMA, ionomycin and brefeldin for 5 hr. AT macrophages (CD45+CD11b+F4/
(E) Quantification D-percentage of AT macrophages expressing TNFa, IL-1b or b
*p < 0.05 versus LPS-activated cells without PAHSA treatment (A–C) or control c
all other groups by two-way ANOVA. Data are means ± SEM. See also Figure S5Administration of 9-PAHSA normalized the percentage of TNFa
positive ATMs and reduced the percentage of IL-1b positive
and double-positive ATMs (Figure 7D). Total ATM number was
not reduced due to the short treatment duration (data not
shown). This demonstrates that PAHSAs have anti-inflammatory
effects in vivo. Therefore, reduced PAHSA levels in insulin-
resistant states (Figures 3A and 4) could contribute to activation
of the innate immune system, thus playing a role in AT inflam-
mation and systemic insulin-resistance.
DISCUSSION
Adipose-Glut4 levels in humans are tightly associated with
insulin sensitivity and lower Glut4 levels confer increased T2D
risk (Carvalho et al., 2001; Shepherd and Kahn, 1999). Adipose-
specific Glut4 overexpression inmice (AG4OX) causes beneficial
metabolic effects which result from enhanced ChREBP-driven
de novo lipogenesis in adipose tissue (AT) (Herman et al.,
2012; Tozzo et al., 1995). Because this occurs even in the setting
of obesity and elevated serum fatty acids (Herman et al., 2012;
Tozzo et al., 1995), we sought to determine whether the
augmented lipogenesis in AG4OX mice leads to production of
lipid species that have favorable metabolic effects. Here we
report the discovery of a class ofmammalian lipids characterized
by a branched ester linkage between a fatty-acid and a hydroxy-
fatty acid or FAHFAs. The closest reported structures are
(O-acyl)-omega hydroxy-fatty acids in the eye (Butovich et al.,
2009), which are not branched.
Of the 16 FAHFA family members we report here, we exten-
sively characterized the biology of PAHSA isomers that are pre-
sent in many, if not all, tissues and in serum in normal mice and
in human WAT and serum (Figures 1, 2, 3, and 4). Total PAHSA
levels are highest in WAT and BAT that also have the greatest
number of PAHSA isomers (Figure 2). Furthermore, PAHSA
levels are highly elevated in serum, WAT and BAT of AG4OX
mice that are obese but have markedly enhanced glucose toler-
ance (Herman et al., 2012; Shepherd et al., 1993). In parallel,
nearly all PAHSA isomers are higher in serum and SQ WAT of
insulin-sensitive humans compared to insulin-resistant humans.
In insulin-resistant, obese mice, PAHSA isomer levels show
adipose-depot-specific regulation and all PAHSA isomers are
lower in SQ WAT of obese compared to lean mice (Figure 3).
These results in SQ WAT are similar to those in insulin-resistantitro and Proinflammatory Cytokine Production from Adipose Tissue
+ cells expressing costimulatory molecules, CD80, CD86, CD40, and MHCII).
ehicle (DMSO) control. Quantification of CD11c+ cells which are positive for
HSA. Red triangles represent vehicle for 9-PAHSA (DMSO) without LPS. MFI:
trations of 9-PAHSA compared to vehicle for 9-PAHSA (DMSO, ‘‘-’’) control.
e/group.
-1b. Mice fed on HFD or chow mice were gavaged for 3 days with 9-PAHSA
was harvested on day 4 and the stromal vascular cells were incubated in vitro
80+) were stained intracellularly for TNFa and IL-1b.
oth. n = 5 mice/group. LPS concentration is 100 ng/ml for all panels.
ells, same diet (E) by one-way (A–C) and two-way ANOVA (D). #p < 0.05 versus
.
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people (Figure 4). 5-PAHSA is consistently reduced in all adipose
depots studied and in serum in insulin-resistant mice and
humans. In insulin-resistant people, most PAHSA isomers are
reduced in serum and AT and correlate highly with insulin sensi-
tivity (Figure 4). ChREBP is required to maintain normal PAHSA
levels in WTmice and elevated levels in AG4OXmice (Figure 1F).
In humans, ChREBP and lipogenic enzyme expression correlate
strongly with insulin-sensitivity. Thus, the reduction in PAHSAs
in insulin-resistant people may be mediated by suppressed
ChREBP expression.
This class of lipids has multiple effects that improve glucose-
insulin homeostasis which suggests that restoring PAHSA levels
in insulin-resistant people could have beneficial metabolic
effects. Oral PAHSA administration in insulin-resistant mice
on a HFD rapidly lowers ambient glucose and also improves
glucose tolerance (Figures 5A and 5B). This may result, at least
in part, from enhanced glucose transport since PAHSAs
augment insulin-stimulated glucose transport and Glut4 trans-
location directly in adipocytes in vitro (Figure 6). In addition,
PAHSAs stimulate both insulin and GLP-1 secretion (Figures
5D–5G). Importantly, the effects of PAHSAs on insulin secretion
are observed only under hyperglycemic conditions (Figure 5F).
The enhanced GSIS in vivo most likely results from both direct
effects on islet cells and indirect effects though GLP-1-stimu-
lated insulin secretion.
Total PAHSA levels in tissues and serum are similar to concen-
trations of signaling lipids such as prostacyclins, prostaglandins,
steroids, and endocannabinoids. PAHSAs are signaling lipids
that directly bind to and activate GPR120 in a cell-based
GPCR activity assay (Figure 6C). GPR120 activation appears
to explain the effects on insulin-induced Glut4 translocation
and glucose uptake in adipocytes (Figures 6B–6D) and may
explain the effects on GLP-1 secretion and inhibition of inflam-
matory responses in immune cells. Thus, PAHSAs are endoge-
nous GPR120 ligands and may also exert effects through other
lipid-activated GPCRs.
PAHSAs have striking anti-inflammatory effects and largely
block LPS-stimulated dendritic cell activation and cytokine
production (Figure 7). Chronic, low-grade inflammation in AT
plays an important role in obesity-related insulin resistance
(Lumeng and Saltiel, 2011; Olefsky and Glass, 2010). Three
days of PAHSA gavage in HFD-fedmice reduced the percentage
of ATMs that express proinflammatory cytokines (Figure 7D).
Therefore, anti-inflammatory effects of PAHSAs may promote
insulin sensitivity and ameliorate other inflammatory diseases.
Insulin-sensitizing and anti-inflammatory effects and GLP-1
secretion are also observed with u-3 fatty acids (Hirasawa
et al., 2005; Oh et al., 2010). However, a major difference
between u-3 fatty acids and PAHSAs is that PAHSAs are syn-
thesized endogenously as evidenced by PAHSA biosynthetic
activity in adipose and liver lysates and incorporation of modified
precursors into FAHFAs in vivo (Figures 3C and 3D). The poten-
tial importance of identifying an endogenous GPR120 ligand
is demonstrated by the fact that loss of function mutations in
GPR120 in humans promote obesity and insulin resistance (Ichi-
mura et al., 2012). Thus, GPR120 is an important control point
in the integration of anti-inflammatory and systemic insulin-
sensitizing responses and is emerging as an important regulator330 Cell 159, 318–332, October 9, 2014 ª2014 Elsevier Inc.of whole-body glucose-insulin homeostasis (Mo et al., 2013). It is
the subject of ongoing preclinical investigation for the treatment
of obesity-related insulin resistance, T2D, and inflammatory dis-
eases (Mo et al., 2013; Oh et al., 2014).
Reduced PAHSA levels may contribute to diabetes risk since
many PAHSA isomers are reduced in SQ WAT and serum of
insulin-resistant rodents (Figure 3A) and humans (Figure 4). In
humans,PAHSA levels inboth serumandSQWATcorrelate high-
ly with whole-body insulin-sensitivity (Figures 4B and 4D). Thus,
reduced circulating PAHSA levels may serve as a biomarker for
insulin resistance andT2D risk. PAHSAs lower glycemia, improve
glucose tolerance and stimulate GLP-1 and insulin secretion in
mice (Figure 5). This raises the possibility that restoring the
reduced PAHSA levels in insulin-resistant humans could have
therapeutic effects to prevent or ameliorate insulin resistance
and T2D. The discovery of the FAHFAs is important also because
their presence suggests uncharacterized biochemical pathways
and enzymes that may be important in human physiology and
disease. Changes in the levels of these metabolites and in their
signaling pathways may provide important insights and new
treatment avenues for metabolic and inflammatory diseases.
EXPERIMENTAL PROCEDURES
Materials and Reagents
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise stated.
Culture and Differentiation of Cells
3T3-L1 fibroblasts were cultured and differentiated as described (Norseen
et al., 2012). STC-1 cells were maintained in DMEM supplemented with 10%
FCS, pen/strep and maintained at 37C and 5% CO2.
Pancreatic Islets, GSIS, and GLP-1 Secretion Studies
Human islets from nondiabetic donors were obtained from Prodo Laboratories
(Irvine, CA). GSIS studies (Kowluru et al., 2010) andGLP-1 secretion fromSTC-
1 cells (Hirasawa et al., 2005) were performed as described.
Generation and Treatment of Bone-Marrow-Derived Dendritic Cells
BMDCs were generated as described (Moraes-Vieira et al., 2014). Cells were
incubated with 9-PAHSA 10 min prior to LPS (100 ng/ml) stimulation. CD11c,
MHC II, CD40, CD80 and CD86 (all Biolegend) were detected by flow cytom-
etry as described (Moraes-Vieira et al., 2014). Cytokine levels were measured
by ELISA (Biolegend).
9-PAHSA Biosynthetic Activity Assay
Liver and PG-WAT tissue was Dounce homogenized in buffer A (10 mM
Tris-HCL (pH 7.4), 250 mM Sucrose containing protease inhibiters (Roche)).
Lysates were centrifuged at 1,200 g to remove incompletely lysed cells and
debris. Lysates were then adjusted to 1 mg/ml protein and 100 ml was incu-
bated with 100 mM palmitoyl-CoA and 100 mM 9-hydroxy stearic acid (PAHSA
substrates) for 2 hr at 37C. Control samples were heat denatured by boiling
for 10 min prior to incubation with PAHSA substrates. After 2 hr the reaction
was stopped by the addition of 300 ml cold buffer A followed by 400 ml of
methanol (MeOH) and 800 ml of chloroform. Samples were vortexed and
centrifuged at 1,200 g for 5 min. 9-PAHSA levels in the organic layer were
measured by LC-MS.
FAHFA Synthesis In Vivo
Two hours postfood removal C57B6/J mice were gavagedwith 25mg/Kg of 9-
hydroxy heptadecanoic acid or vehicle. Three hours later mice were sacrificed
and serum was collected. Serum lipids were extracted and 9-PAHHA levels
measured by LC-MS.
Animal Studies and Measurement of Metabolic Parameters
Female AG4OXmice andWT FVB littermate controls (Shepherd et al., 1993) at
8–14 weeks old were used for FAHFA tissue distribution and regulation with
fasting and HFD studies. ChREBP-KO, ChREBP-KO/AG4OX and control
females (Herman et al., 2012) were used at 16–18 weeks old. Mice were fed
on chow (Lab Diet, 5008) or HFD (Harlan Teklad, TD.93075) for 9 weeks (female
FVB) or 42–52 weeks (male C57BL6/J). OGTT’s were performed as described
(Moraes-Vieira et al., 2014) after 5 hr food removal.
Anti-Inflammatory Effects of 9-PAHSA In Vivo
Male C57BL6/J mice on chow or HFD described above were gavaged once
a day for 3 days with 30 mg/kg (chow) or 45 mg/kg (HFD) of 9-PAHSA
or an equivalent volume of vehicle. On the 4th day PG stromal vascular
fraction (SVF) cells were harvested and cultured for 5 hr with ionomycin,
PMA and brefeldin at 37C and the intracellular cytokine content was
measured in gated CD45+, CD11b+, and F4/80+ cells as described (Moraes-
Vieira et al., 2014).
Human Studies
Hyperinsulinemic-euglycemic clamp was performed in 13 nondiabetic sub-
jects. SQ WAT biopsies were obtained from the peri-umbilical, abdominal
region after an overnight fast.
Lipid Extraction
Lipid extraction was performed as described (Bligh and Dyer, 1959; Sagha-
telian et al., 2004). Tissues (60–150 mg) were Dounce homogenized on
ice in a mixture of 1.5 ml MeOH, 1.5 ml chloroform and 3 ml citric acid
buffer. PAHSA standards were added to chloroform prior to extraction.
The resulting mixture was centrifuged and the organic phase containing ex-
tracted lipids was dried under N2 and stored at 80C prior to solid phase
extraction.
Lipidomic Analysis
Lipidomic analysis was performed using an Agilent 6220 ESI-TOF fittedwith an
electrospray ionization source with a capillary voltage of 3,500 kV and frag-
mentor voltage of 100 V. A Gemini C18 reversed phase column (Phenomenex)
and a C18 reversed phase guard column (Western Analytical) was used for
LC-MS analysis in negativemode. In positive mode, a Luna C5 reversed phase
column (Phenomenex) was used together with a C4 reversed phase guard
column (Western Analytical). Drying gas temperature was 350C, flow rate
10 l/min and nebulizer pressure 45 psi. Untargeted data were collected using
an m/z of 100–1,500.
ADD
Structural characterization of the FAHFAs by MS/MS was carried out on an
Agilent 6510 quadrupole-time of flight MS.
Synthesis of PAHSAs and PAHSA Standards
Detailed information on synthesis of PAHSAs and PAHSA standards is outlined
in the Supplemental Information.
Targeted LC/MS Analysis of FAHFAs
FAHFAs were measured on an Agilent 6410 Triple Quad LC/MS via Multiple
Reaction Monitoring in negative ionization mode. Extracted and fractionated
samples were reconstituted in 25 ml MeOH; 10 ml was injected for analysis.
A Luna C18(2) (Phenomenex) column was used with an in-line filter (Phe-
nomenex). Distinct PAHSA species were resolved via isocratic flow at
0.2 ml/min for 120 min using 93:7 MeOH:H2O with 5 mM ammonium acetate
and 0.01% ammonium hydroxide as solvent. Transitions for endogenous
PAHSAs were m/z 537.5 / m/z 255.2 (Collision Energy [CE] = 30 V), m/z
537.5 / m/z 281.2 (CE = 25 V), and m/z 537.5 / m/z 299.3 (CE = 23 V),
and the transition for 13C-9-PAHSA was m/z 553.5 / m/z 271.3 (CE =
30 V), all FAHFA transitions are listed in Supplemental Information.
Data Analysis
All values are means ± SEM. Differences between groups were assessed
using unpaired two-tailed Student’s t tests and/or ANOVA with Fisher’s LSDmultiple comparisons as specified in figure legends. All statistical analyses
were performed with GraphPad Prism 5.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, four tables, and one data file and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2014.09.035.
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